The Administrative Unit (AU) of the Primary Immune Deficiency Treatment Consortium (PIDTC) is responsible forthe overall development and achievement of the scientific goals of the PIDTC. The goals of the AU are 1) to provide leadership in order to achieve the PIDTC objectives;2) to provide support and direction for each of the research protocols including development of protocols and consents, regulatory management, establishment and achievement of goals for case report form (CRF) completion, and maintaining datasets and statistical analysis of data for manuscript preparation;and 3) to facilitate development of future initiatives by the PIDTC in order to maintain its leadership role in the field of primary immune deficiency (PID). To this end, the AU has directed and initiated comprehensive studies of Severe Combined Immunodeficiency Disease, Chronic Granulomatous Disease and Wiskott Aldrich Syndrome in addition to organizing and leading the 33 PIDTC centers.
The Specific Aim ofthe AU is: To provide overall leadership to the PIDTC through organization of the Steering Committee, Scientific Planning Committee, Training committee. Pilot Project Committee, Protocol Planning Committees, the Publication Committee and the PAG Committee. Through this organization the AU will: a) Ensure that the protocols and consents are efficiently developed and implemented and that centers achieve their goals of enrollment and completion of CRFs in a timely manner;b) Maintain acfive collaboration with the Data Management and Coordinating Committee (DMCC) for implementation of protocols and CRFs, audifing of centers, import/export of data, and training of study personnel at PIDTC centers;c) Maintain active communications with PAGs, to ensure PAG representation on PIDTC committees, and to develop a productive scientific collaborafion with the PAGs in order to maximize our understanding of PIDs;d) Foster interest and participation of trainees and junior faculty in the PIDTC to generate the next generafion of leaders in the field;e) Ensure that results of scientific progress made by each of the research projects are effectively communicated to all PIDTC members, PAGs, and the rest ofthe scientific community;f) Promote the collaborafion of the PIDTC with colleagues outside of North America;and g) Continually promote the development of new ideas and inifiatives within the PIDTC scientific community, in particular, the design and implementation of prospective multicenter clinical trials that will optimize the care and definitive cure of PIDs.

Public Health Relevance

The ongoing and proposed PIDTC studies that will lead to identification of powerful biomarkers that predict outcome of hematopoietic cell transplantation for children with these rare life-threatening diseases and form the basis for future clinical trials to optimize definitive care could only be accomplished through the leadership and organizafion ofthe PIDTC and its Administrative Unit.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Chinen, Javier; Cowan, Morton J (2018) Advances and highlights in primary immunodeficiencies in 2017. J Allergy Clin Immunol 142:1041-1051
Miggelbrink, Alexandra M; Logan, Brent R; Buckley, Rebecca H et al. (2018) B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 131:2967-2977
Slack, James; Albert, Michael H; Balashov, Dmitry et al. (2018) Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol 141:322-328.e10
Langelier, Charles; Zinter, Matt S; Kalantar, Katrina et al. (2018) Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients. Am J Respir Crit Care Med 197:524-528
Haddad, Elie; Logan, Brent R; Griffith, Linda M et al. (2018) SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood 132:1737-1749
Barzaghi, Federica; Amaya Hernandez, Laura Cristina; Neven, Benedicte et al. (2018) Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol 141:1036-1049.e5
Kuo, Caroline Y; Long, Joseph D; Campo-Fernandez, Beatriz et al. (2018) Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome. Cell Rep 23:2606-2616
Belderbos, Mirjam E; Gennery, Andrew R; Dvorak, Christopher C et al. (2018) Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. J Allergy Clin Immunol 142:1628-1631.e4
Buchbinder, David; Smith, Matthew J; Kawahara, Misako et al. (2018) Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency. Blood Adv 2:1828-1832
Kohn, Donald B; Hershfield, Michael S; Puck, Jennifer M et al. (2018) Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol :

Showing the most recent 10 out of 88 publications